Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

被引:120
|
作者
Chang, Woo-Sung [1 ,2 ]
Kim, Ji-Yeon [1 ,2 ]
Kim, Yeon-Jeong [1 ,2 ]
Kim, Yun-Sun [1 ,2 ]
Lee, Jung-Mi [1 ,2 ]
Azuma, Miyuki [3 ]
Yagita, Hideo [4 ]
Kang, Chang-Yuil [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Immunol Lab, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[3] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
[4] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
来源
JOURNAL OF IMMUNOLOGY | 2008年 / 181卷 / 10期
关键词
D O I
10.4049/jimmunol.181.10.6707
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Invariant NKT (iNKT) cells are a distinct subset of T lymphocytes that recognize glycolipid Ags. Upon TCR stimulation, iNKT cells promptly secrete a wide range of cytokines and therefore have been investigated as a target for immunotherapy. However, after primary activation, iNKT cells become hyporesponsive toward their ligand (anergy). The further mechanism behind iNKT cell anergy is poorly understood. We found that a low level of programmed death-1 (PD-1) was constitutively expressed on iNKT cells and that PD-1 expression was increased after stimulation and lasted at least 2 mo. Moreover, not only did blocking of the PD-1/PD ligand 1 (PD-L1) pathway prevent the induction of anergy in iNKT cells, but anergic NKT cells also recovered responsiveness and these "rescued" cells efficiently mediated antitumor immunity. Our findings suggest that the PD-1/PD-L1 interaction is essential for the induction and maintenance of iNKT cell anergy. The Journal of Immunology, 2008,181: 6707-6710.
引用
收藏
页码:6707 / 6710
页数:4
相关论文
共 50 条
  • [41] Transarterial chemoembolisation enhances programmed death-1 and programmed death ligand-1 expression in hepatocellular carcinoma
    Montasser, A.
    Beaufrere, A.
    Cauchy, F.
    Soubrane, O.
    Colnot, N.
    Tessiore, S.
    Albuquerque, M.
    Paradis, V.
    VIRCHOWS ARCHIV, 2019, 475 : S20 - S20
  • [42] Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.
    Wang, Hanping
    Guo, Xiaoxiao
    Tian, Ran
    Si, Xiaoyan
    Zhang, Xiaotong
    Wang, Jiangshan
    Zhao, Haitao
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?
    Owen, Dwight H.
    Otterson, Gregory A.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4069 - S4072
  • [44] Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
    Chen, Zhifang
    Pang, Nannan
    Du, Rong
    Zhu, Yuejie
    Fan, Lingling
    Cai, Donghui
    Ding, Yan
    Ding, Jianbing
    MEDIATORS OF INFLAMMATION, 2016, 2016
  • [45] Programmed cell death-1 inhibition in lymphoma
    Hawkes, Eliza A.
    Grigg, Andrew
    Chong, Geoff
    LANCET ONCOLOGY, 2015, 16 (05): : E234 - E245
  • [46] Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction
    Fang, Lincheng
    Tian, Jiping
    Zhang, Kaixuan
    Zhang, Xiaoyi
    Liu, Yingqiao
    Cheng, Zhibo
    Zhou, Jinpei
    Zhang, Huibin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 46
  • [47] Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
    Toshiko Kamata
    Akane Suzuki
    Naoko Mise
    Fumie Ihara
    Mariko Takami
    Yuji Makita
    Atsushi Horinaka
    Kazuaki Harada
    Naoki Kunii
    Shigetoshi Yoshida
    Ichiro Yoshino
    Toshinori Nakayama
    Shinichiro Motohashi
    Cancer Immunology, Immunotherapy, 2016, 65 : 1477 - 1489
  • [48] Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer
    Remon, Jordi
    Chaput, Nathalie
    Planchard, David
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) : 122 - 129
  • [49] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [50] Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kondo, Tsunenori
    Shinohara, Nobuo
    Nonomura, Norio
    Ozono, Seiichiro
    Eto, Masatoshi
    Tatsugami, Katsunori
    Takayama, Tatsuya
    Matsuyama, Hideyasu
    Kishida, Takeshi
    Oya, Mototsugu
    CANCER SCIENCE, 2019, 110 (06) : 1820 - 1828